Effect of intermittent versus continuous parathyroid hormone in the cardiovascular system of rats

Open Cardiovascular Medicine Journal

Volumn 4, Issue , 2010, Pages 110-116

  Smajilovic, Sanela ^c   Schaal Jensen, Rasmus ^a,b   Jabbari, Reza ^a,b   Smajilovic, Una ^a   Haunso, Stig ^a   Tfelt Hansen, Jacob ^a,b  

^a Mental Health Services CPH   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Continuous; Intermittently; Pth

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CALCIUM ION; COLLAGEN TYPE 1; COLLAGEN TYPE 3; FIBRONECTIN; MESSENGER RNA; PARATHYROID HORMONE; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM BLOOD LEVEL; CONTINUOUS INFUSION; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSAGE SCHEDULE COMPARISON; DRUG INTERMITTENT THERAPY; HEART LEFT VENTRICLE MASS; HEART MUSCLE FIBROSIS; HEART RATE; HEART VENTRICLE HYPERTROPHY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC BLOOD PRESSURE;

EID: 78249284640     PISSN: None     EISSN: 18741924     Source Type: Journal    
DOI: 10.2174/1874192401004010110     Document Type: Article

References (28)

1. Smajilovic S, Tfelt-Hansen J. Calcium acts as a first messenger through the calcium-sensing receptor in the cardiovascular system. Cardiovasc Res 2007; 75: 457-467.
2. Pocotte SL, Ehrenstein G, Fitzpatrick LA. Regulation of parathy-roid hormone secretion. Endocr Rev 1991; 12: 291-301.
3. Tfelt-Hansen J, Schwarz P, Brown EM, Chattopadhyay N. The calcium-sensing receptor in human disease. Front Biosci 2003; 8: s377-390.
4. Girotra M, Rubin MR, Bilezikian JP. The use of parathyroid hormone in the treatment of osteoporosis. Rev Endocr Metab Disord 2006; 7: 113-121.
5. Poole KE, Reeve J. Parathyroid hormone - a bone anabolic and catabolic agent. Curr Opin Pharmacol 2005; 5: 612-617.
6. Bro S, Olgaard K. Effects of excess PTH on nonclassical target organs. Am J Kidney Dis 1997; 30: 606-620.
7. Urena P, Kong XF, Abou-Samra AB, et al. Parathyroid hormone (PTH)/PTH-related peptide receptor messenger ribonucleic acids are widely distributed in rat tissues. Endocrinology 1993; 133: 617-623.
8. Qian J, Colbert MC, Witte D, et al. Midgestational lethality in mice lacking the parathyroid hormone (PTH)/PTH-related peptide receptor is associated with abrupt cardiomyocyte death. Endocrinology 2003; 144: 1053-1061.
9. Bernardi D, Bernini L, Cini G, et al. Asymmetric septal hypertrophy in uremic-normotensive patients on regular hemodialysis. An M-mode and two-dimensional echocardiographic study. Nephron 1985; 39: 30-35.
10. London GM, De Vernejoul MC, Fabiani F, et al. Secondary hyperparathyroidism and cardiac hypertrophy in hemodialysis patients. Kidney Int 1987; 32: 900-907.
11. Sato S, Ohta M, Kawaguchi Y, et al. Effects of parathyroidectomy on left ventricular mass in patients with hyperparathyroidism. Miner Electrolyte Metab 1995; 21: 67-71.
12. Hara S, Ubara Y, Arizono K, et al. Relation between parathyroid hormone and cardiac function in long-term hemodialysis patients. Miner Electrolyte Metab 1995; 21: 72-76.
13. Saleh FN, Schirmer H, Sundsfjord J, Jorde R. Parathyroid hormone and left ventricular hypertrophy. Eur Heart J 2003; 24: 2054-2060.
14. Schluter KD, Piper HM. Trophic effects of catecholamines and parathyroid hormone on adult ventricular cardiomyocytes. Am J Physiol 1992; 263: H1739-1746.
15. Bogin E, Massry SG, Harary I. Effect of parathyroid hormone on rat heart cells. J Clin Invest 1981; 67: 1215-1227.
16. Bogin E, Harary I. The relationship of calcium and parathyroid hormone in their effect on heart cells. Mol Cell Biochem 1987; 77: 29-35.
17. Laursen JB, Mulsch A, Boesgaard S, et al. In vivo nitrate tolerance is not associated with reduced bioconversion of nitroglycerin to nitric oxide. Circulation 1996; 94: 2241-2247.
18. Tfelt-Hansen J, Schwarz P, Torring O. Rapid suppression of S-PTH by oral calcitriol and calcium in healthy premenopausal women. Scand J Clin Lab Invest 2001; 61: 395-400.
19. Tfelt-Hansen J, Schwarz P, Terwilliger EF, Brown EM, Chattopadhyay N. Calcium-sensing receptor induces messenger ribonucleic acid of human securin, pituitary tumor transforming gene, in rat testicular cancer. Endocrinology 2003; 144: 5188-5193.
20. Schluter KD, Piper HM. Cardiovascular actions of parathyroid hormone and parathyroid hormone-related peptide. Cardiovasc Res 1998; 37: 34-41.
21. Pang PK, Tenner TE, Jr., Yee JA, Yang M, Janssen HF. Hypotensive action of parathyroid hormone preparations on rats and dogs. Proc Natl Acad Sci USA 1980; 77: 675-678.
22. Fliser D, Franek E, Fode P, et al. Subacute infusion of physiological doses of parathyroid hormone raises blood pressure in humans. Nephrol Dial Transplant 1997; 12: 933-938.
23. Zaruba MM, Huber BC, Brunner S, et al. Parathyroid hormone treatment after myocardial infarction promotes cardiac repair by enhanced neovascularization and cell survival. Cardiovasc Res 2008; 77: 722-731.
24. Ogata H, Ritz E, Odoni G, Amann K, Orth SR. Beneficial effects of calcimimetics on progression of renal failure and cardiovascular risk factors. J Am Soc Nephrol 2003; 14: 959-967.
25. Shimoyama M, Ogino K, Furuse Y, et al. Signaling pathway and chronotropic action of parathyroid hormone in isolated perfused rat heart. J Cardiovasc Pharmacol 2001; 38: 491-499.
26. DiPette DJ, Christenson W, Nickols MA, Nickols GA. Cardiovascular responsiveness to parathyroid hormone (PTH) and PTH-related protein in genetic hypertension. Endocrinology 1992; 130: 2045-2051.
27. Fritsch S, Lindner V, Welsch S, et al. Intravenous delivery of PTH/PTHrP type 1 receptor cDNA to rats decreases heart rate, blood pressure, renal tone, renin angiotensin system, and stress-induced cardiovascular responses. J Am Soc Nephrol 2004; 15: 2588-600.
28. Bernardi D, Bernini L, Cini G, Ghione S, Bonechi I. Asymmetric septal hypertrophy and sympathetic overactivity in normotensive hemodialyzed patients. Am Heart J 1985; 109: 539-545.